Announcements
- Hofseth Biocare ASA: FIRST QUARTER 2024 FINANCIAL REPORT
- Hofseth Biocare ASA: Annual General Meeting completed
- Hofseth Biocare ASA: NOTICE OF ANNUAL GENERAL MEETING 2024
- Hofseth Biocare ASA: HBC ANNUAL REPORT 2023
- Hofseth Biocare ASA: DISCLOSURE OF LARGE SHAREHOLDING
- Hofseth Biocare ASA: UPDATED COMPANY PRESENTATION
- Hofseth Biocare ASA: CHAIR KRISTIN FJELLBY GRUNG STEPS DOWN
- Hofseth Biocare ASA: FOURTH QUARTER 2023 AND FULL YEAR FINANCIAL REPORT
- Hofseth Biocare ASA: HBC Immunology Inc successfully completes first animal model of prostate cancer with FT-005 in combination with hormonal (anti-androgen) therapy demonstrating significant anti-tumour activity
- Hofseth Biocare ASA: SHARE CAPITAL INCREASE REGISTERED
More ▼
Key statistics
As of last trade Hofseth Biocare ASA (0Q6H:LSE) traded at 0.00, -100.00% above its 52-week low of 2.16, set on Mar 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 2.16 |
Average volume | -- |
---|---|
Shares outstanding | 395.08m |
Free float | 165.07m |
P/E (TTM) | -- |
Market cap | 829.67m NOK |
EPS (TTM) | -0.2449 NOK |
Data delayed at least 20 minutes, as of Dec 30 1899.
More ▼